- Al-Batran, S., Wainberg, Z., Muro, K., Molena, D., Van Cutsem, E., Hyung, W.,…Tabernero, J., Janjigian, Y. (2025). Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma. Annals of Oncology, 36. https://doi.org/10.1016/j.annonc.2025.05.544 (Meeting abstract)
Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma
on 1 de desembre de 2025
with No hi ha comentaris
Deixa un comentari